|
|
Thousands of dollars except share and per share data
|
|
Year ended August 31
|
1 9 9 8
|
1997
|
1996
|
1995
|
1994
|
|
|
Operating Data
|
SALES
|
|
$163,045
|
$170,057
|
$168,018
|
$149,663
|
$136,259
|
GROSS MARGIN PERCENTAGE
|
|
28.0%
|
25.2%
|
23.4%
|
26.5%
|
24.7%
|
INCOME FROM OPERATIONS
|
|
18,2291
|
17,469
|
15,264
|
16,619
|
12,640
|
INCOME FROM CONTINUING OPERATIONS
|
|
8,110
|
8,9342
|
6,969
|
8,2693
|
7,214
|
EARNINGS PER COMMON SHARE FROM CONTINUING OPERATIONS, DILUTED
|
|
1.08
|
1.25
|
0.99
|
1.18
|
1.01
|
DIVIDENDS DECLARED PER COMMON SHARE
|
0.20
|
0.20
|
0.20
|
0.20
|
0.20
|
WEIGHTED AVERAGE COMMON SHARES AND EQUIVALENTS OUTSTANDING
|
|
7,530,640
|
7,131,725
|
7,007,340
|
7,018,970
|
7,110,953
|
|
|
Balance Sheet Data
|
NET PROPERTY, PLANT AND EQUIPMENT
|
|
$107,049
|
$108,099
|
$100,463
|
$ 91,067
|
$ 81,583
|
CAPITAL EXPENDITURES
|
|
10,768
|
18,349
|
19,447
|
18,659
|
10,620
|
TOTAL DEBT
|
73,896
|
67,746
|
66,763
|
62,898
|
46,997
|
SHAREHOLDERS' EQUITY
|
|
53,995
|
89,101
|
78,572
|
72,476
|
67,527
|
TOTAL ASSETS
|
|
183,208
|
213,508
|
200,317
|
184,261
|
136,128
|
Note
|
All data exept share and per share data has been restated to reflect the distribution of 100% of the common stock of Penwest Pharmaceuticals Co. (PPCO) to the shareholders of Penford Corporation which was completed on August 31, 1998.
|
1
|
Includes a pretax charge of approximately $1.9 million ($1.3 million after-tax, or $0.17 per share) related to restructure costs recorded in connection with the spin-off of PPCO.
|
|
2
|
Includes a pretax gain of approximately $1.2 million ($800,000 after-tax, or $0.11 per share) related to the sale of Southern California air emission credits.
|
|
3
|
Includes a pretax gain of approximately $899,000 ($580,000 after-tax, or $0.08 per share) related to the sale of assets of Pacific Cogeneration, Inc.
|
|
|
